2025
Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden.
Palencia P, Zhao X, Kandala K, Smani S, Sivanesan N, Cavallo J, Leapman M. Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17123.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyProstate radiation therapyMetastatic prostate cancerOverall survivalRadiation therapyProstate cancerM1c diseaseTreatment modalitiesRT to ADTTreated with androgen deprivation therapyAssociated with improved overall survivalHormone-sensitive prostate cancerAssociated with poor overall survivalPrimary local therapyExternal beam radiotherapyGleason grade groupCompare overall survivalNational Cancer DatabaseProstate cancer metastasisLog-rank testDisease burdenKaplan-Meier curvesCox proportional hazards modelsLow disease burdenProstate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis
Miszczyk M, Fazekas T, Rajwa P, Matsukawa A, Tsuboi I, Leapman M, Kramer G, Hussain M, Merseburger A, Briganti A, D'Amico A, Gillessen S, Saad F, Shariat S. Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus 2025 PMID: 40379533, DOI: 10.1016/j.euf.2025.03.019.Peer-Reviewed Original ResearchAndrogen receptor pathway inhibitorsPSA responseProstate-specific antigen reductionAssociated with better OSProstate-specific antigenAndrogen deprivation therapyCastration-resistant PCOverall survivalProstate cancerTreated with androgen deprivation therapyHazard ratioMetastatic castration-resistant PCMetastatic hormone-sensitive PCNonmetastatic castration-resistant PCProstate-specific antigen responsePathway inhibitorBaseline PSA measurementHormone-sensitive PCUndetectable PSA levelsAdvanced prostate cancerAssociated with OSRandom-effects meta-analysesDeprivation therapyPSA levelsPSA measurements
2009
Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy
Choueiri T, Xie W, D'Amico A, Ross R, Hu J, Pomerantz M, Regan M, Taplin M, Kantoff P, Sartor O, Oh W. Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy. Cancer 2009, 115: 981-987. PMID: 19152438, PMCID: PMC2931827, DOI: 10.1002/cncr.24064.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapy initiationProstate-specific antigen nadirHormone-sensitive prostate cancerMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyProstate-specific antigenInitiation of androgen deprivation therapyTreated with androgen deprivation therapyGleason score >7Overall survivalPSA declineShorter OSProstate cancerKinetics of prostate-specific antigenResponse to ADTNadir prostate-specific antigenProstate-specific antigen declineAssociated with shorter OSAssociated with shorter survival durationMedian PSA levelSerum PSA valuesSerum PSA determinationMedian Follow-UpAuthors' institutional databaseShorter survival duration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply